Free tool
FAERS Monitor: Tavalisse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209299 or its brand name (Tavalisse, Fostamatinib Disodium). Reports on generic versions are filed under their own applications.
Reports
7,889
Serious
2,613
33% of reports
Hospitalization
1,819
Death reported
493
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,068
- product dose omission issue1,026
- platelet count decreased1,019
- off label use873
- hospitalisation508
- platelet count498
- drug ineffective433
- fatigue403
- blood pressure increased384
- death342
- product prescribing issue316
- headache273
- nausea250
- dizziness229
- hypertension208
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 155 |
| 2019 | 619 |
| 2020 | 650 |
| 2021 | 454 |
| 2022 | 773 |
| 2023 | 1,119 |
| 2024 | 1,302 |
| 2025 | 1,325 |
| 2026 | 1,490 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,270 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| platelet countSignal | 498 | 16402.0 | 12982.8 | 1,140,301 |
| product prescribing issueSignal | 316 | 39.2 | 35.2 | 11,575 |
| platelet count decreasedSignal | 1,019 | 25.7 | 24.3 | 24,082 |
| product dose omission issueSignal | 1,026 | 9.3 | 8.8 | 7,705 |
| hospitalisationSignal | 508 | 8.8 | 8.1 | 3,539 |
| blood pressure increasedSignal | 384 | 6.7 | 6.1 | 1,869 |
| diarrhoeaSignal | 1,068 | 4.4 | 4.2 | 2,904 |
| off label useSignal | 873 | 2.7 | 2.5 | 941 |
| hypertensionSignal | 208 | 2.6 | 2.3 | 209 |
| fatigue | 403 | 1.4 | 1.3 | 43 |
| dizziness | 229 | 1.2 | 1.1 | 9 |
| headache | 273 | 1.2 | 1.0 | 6 |
| death | 342 | 1.1 | 1.0 | 1 |
| drug ineffective | 433 | 0.9 | 0.8 | 8 |
| nausea | 250 | 0.8 | 0.7 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.